A side-by-side comparison of compounded tirzepatide (503A/503B pathway) and brand-name Zepbound® (Eli Lilly): cost, regulatory status, ingredient sourcing, and clinical implications in 2026.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11
Side-by-side comparison
Attribute
Compounded tirzepatide
Zepbound® (brand)
FDA approval status
Not FDA-approved
FDA-approved (chronic weight management, OSA)
Manufacturer
503A or 503B pharmacy
Eli Lilly
Active ingredient
Tirzepatide base (legitimate compounding); salt forms (acetate/sodium) subject to FDA warning letters
Tirzepatide (Eli Lilly proprietary process)
Monthly cash price
$186–$379/mo
$1,059–$1,279/mo (cash MSRP)
Insurance coverage
No (cash-pay only)
Many commercial plans, varies by formulary
HSA/FSA eligible
Yes (with prescription)
Yes
Drug shortage status (FDA Drug Shortage list)
N/A — compounded supply
Resolved (Oct 2024)
Form factor
Multi-dose vial (draw with syringe)
Pre-filled single-dose pen or vial
Quality assurance documentation
USP <71> / USP <85> / HPLC CoA from dispensing pharmacy (provider-dependent)
FDA-inspected cGMP manufacturing
The 503A vs 503B distinction
503A pharmacies are state-licensed compounding pharmacies that prepare patient-specific medications under USP <797> sterile-compounding standards. They are not FDA-inspected for product release. 503B outsourcing facilities are FDA-registered and operate under cGMP standards (the same standard as commercial drug manufacturers). They can prepare batches in advance of patient-specific prescriptions. Read the full 503A vs 503B explainer →
What changed in April 2026
The FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 medications and to crack down on misleading direct-to-consumer marketing. The FDA has previously issued warning letters specifically against compounded GLP-1 salt forms (tirzepatide acetate, tirzepatide sodium). Legitimate compounded tirzepatide must use tirzepatide base only. NexLife dispenses tirzepatide base via 503A and 503B partner pharmacies with published CoAs.
Who is each product right for?
Zepbound: Best fit for patients with commercial insurance that covers GLP-1s for chronic weight management, or who can use the Lilly Savings Card to access affordable pricing.
Compounded tirzepatide: Best fit for cash-pay patients without insurance coverage for brand GLP-1s, who want a pharmacy-traceable, MD/DO-supervised compounded option at a fraction of brand pricing.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
